Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The use of tacrolimus (FK506) as an immunosuppressant is limited by its low aqueous solubility and bioavailability. The self-microemulsifying drug delivery system (SMEDDS) has successfully improved the solubility of FK506 in our previous study. This study focused on the solidification of liquid SMEDDS to capture the benefits of both liquid SMEDDS and solid dosage forms. Among several porous silica adsorbents evaluated, Aeroperl® 300 Pharma showed the best performance in terms of droplet size, in vitro dissolution, adsorbent-drug compatibility, and tabletabilities. And precoating the adsorbent with polyvinylpyrrolidone K30 resulted in complete drug release. Hydroxypropyl methylcellulose based matrix tablet was developed to achieve a sustained release of FK506. Differential scanning calorimetry and X-ray powder diffraction indicated that FK506 was present in a molecular or amorphous state in the solidified SMEDDS and tablets. In vivo pharmacokinetic studies showed that the self-prepared tablet had improved bioavailability (179.02%) compared to the marketed product Advagraf®. This study provided a promising candidate with improved dissolution and bioavailability for FK506 and a prospective platform for SMEDDS development.

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-024-00992-wDOI Listing

Publication Analysis

Top Keywords

liquid smedds
8
fk506
5
smedds
5
development solidified
4
solidified self-microemulsifying
4
self-microemulsifying delivery
4
delivery systems
4
systems tacrolimus
4
tacrolimus enhanced
4
enhanced dissolution
4

Similar Publications

Supersaturatable self-microemulsifying drug delivery system (S-SMEDDS) has recently been utilized to enhance the oral absorption of poorly water-soluble drugs. S-SMEDDS forms drug-incorporated microemulsions (MEs) during aqueous dispersion with the formation of drug supersaturation in the bulk water phase. However, the liquid-liquid phase separation (LLPS) behavior of the supersaturated drugs within MEs has not been well studied.

View Article and Find Full Text PDF

The repurposing of statins as neuroprotective agents and/or anti-brain tumor drugs is limited by challenges in brain bioavailability and systemic off-target effects. Therefore, improved and targeted delivery of statins to the brain is necessary. This study aimed to develop a high-strength liquid formulation of the poorly soluble prodrug simvastatin for intranasal administration, as a strategy to achieve high brain concentrations of the prodrug and/or its active form, tenivastatin.

View Article and Find Full Text PDF

The lack of local availability for drugs in the colon can be addressed by preparing a self-microemulsifying drug delivery system (SMEDDS) of curcumin (Cur) which is ultimately used for the treatment of inflammatory bowel disease (IBD). From preformulation studies, Lauroglycol FCC (oil), Tween 80 (surfactant), Transcutol HP (co-surfactant), and Avicel (solid carrier) were selected for the preparation of blank liquid and solid Cur-loaded SMEDDSs (S-Cur-SMEDDSs). Z-average size (12.

View Article and Find Full Text PDF

Background: Voriconazole is an antifungal drug, which is classified under Bio-Classification System-II and has low water solubility (0.71 mg/mL) and high permeability. Hardly any endeavors have been made to increase the bioavailability of voriconazole.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates improving the delivery of tacrolimus (FK506), an immunosuppressant, by using a self-microemulsifying drug delivery system (SMEDDS) to enhance its solubility and bioavailability.
  • - Liquid SMEDDS was solidified using Aeroperl® 300 Pharma, which showed excellent performance in drug dissolution and compatibility, and achieving complete drug release was facilitated by precoating with polyvinylpyrrolidone K30.
  • - The resulting hydroxypropyl methylcellulose-based tablets demonstrated a significant increase in bioavailability (179.02%) compared to the marketed formulation Advagraf®, suggesting a promising direction for future SMEDDS applications.
View Article and Find Full Text PDF